FLT3 and acute myeloid leukemia: On the other hand, in a study from Shao and colleagues presented at 63rd annual meeting of American Society of Hematology, the concomitant mutation of CEBPA and TET2 neutralized the positive effect of sorafenib in FLT3-ITD-mutated AML [56].